This week's guest is Dr. Bishal Gyawali. Bishal is an oncologist at Queen's University and a policy researcher. His focus as a researcher has been both sensational and at the same time extremely fundamental. Bishal has been asking questions around how we decide which drugs are approved for funding by the government, as well as how we might best allocate resources to help cancer patients around the world. Bishal has been an integral part of the "Common Sense Oncology" movement, which will promote interventions that measurably improve the lives of patients, promoting effective treatments but also challenging interventions that might cause more harm than good.Our conversation focused around Bishal's training, how he became interested in cancer health policy and his thoughts around the idea of value in cancer care. We also discussed Bishal's thoughtful use of technology, blogs, and social media.Links:Grounded in Groundshot Podcast – Dr. Bishal GyawaliBG lab: Dr. Bishal GyawaliCommon Sense Oncology: Home - Common Sense OncologyMittal A, Kim MS, Dunn S, Wright K, Gyawali B. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward. EClinicalMedicine. 2024 Sep 13;76:102824. doi: 10.1016/j.eclinm.2024.102824. PMID: 39764569; PMCID: PMC11701476.Surrogate Endpoints: The 15 Most Common Misunderstandings in OncologyCancer groundshot: Access to proven treatments must parallel development of new therapiesDo Oncology Board Exams Make Us Better Doctors?Ending Medical Reversal: Ending Medical Reversal | Hopkins Press

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related